WO2005112864A3 - Method for fostering bone formation and preservation - Google Patents

Method for fostering bone formation and preservation Download PDF

Info

Publication number
WO2005112864A3
WO2005112864A3 PCT/US2005/016613 US2005016613W WO2005112864A3 WO 2005112864 A3 WO2005112864 A3 WO 2005112864A3 US 2005016613 W US2005016613 W US 2005016613W WO 2005112864 A3 WO2005112864 A3 WO 2005112864A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
bone
osteoblast activity
preservation
elevated
Prior art date
Application number
PCT/US2005/016613
Other languages
French (fr)
Other versions
WO2005112864A2 (en
Inventor
Agnes Vignery
Nozer M Mehta
James P Gilligan
Original Assignee
Unigene Lab Inc
Univ Yale Inc
Agnes Vignery
Nozer M Mehta
James P Gilligan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unigene Lab Inc, Univ Yale Inc, Agnes Vignery, Nozer M Mehta, James P Gilligan filed Critical Unigene Lab Inc
Priority to JP2007513355A priority Critical patent/JP2007537281A/en
Priority to CA002566675A priority patent/CA2566675A1/en
Priority to AU2005244829A priority patent/AU2005244829B2/en
Priority to EP05760624A priority patent/EP1748787A4/en
Publication of WO2005112864A2 publication Critical patent/WO2005112864A2/en
Publication of WO2005112864A3 publication Critical patent/WO2005112864A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Abstract

A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.
PCT/US2005/016613 2004-05-14 2005-05-12 Method for fostering bone formation and preservation WO2005112864A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2007513355A JP2007537281A (en) 2004-05-14 2005-05-12 How to promote and maintain bone formation
CA002566675A CA2566675A1 (en) 2004-05-14 2005-05-12 Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering a bone anabolic agent
AU2005244829A AU2005244829B2 (en) 2004-05-14 2005-05-12 Method for fostering bone formation and preservation
EP05760624A EP1748787A4 (en) 2004-05-14 2005-05-12 Method for fostering bone formation and preservation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US57120004P 2004-05-14 2004-05-14
US60/571,200 2004-05-14
US11/128,095 US7531518B2 (en) 2004-05-14 2005-05-11 Method for fostering bone formation and preservation
US11/128,095 2005-05-11

Publications (2)

Publication Number Publication Date
WO2005112864A2 WO2005112864A2 (en) 2005-12-01
WO2005112864A3 true WO2005112864A3 (en) 2006-05-18

Family

ID=35310174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016613 WO2005112864A2 (en) 2004-05-14 2005-05-12 Method for fostering bone formation and preservation

Country Status (6)

Country Link
US (3) US7531518B2 (en)
EP (1) EP1748787A4 (en)
JP (1) JP2007537281A (en)
AU (1) AU2005244829B2 (en)
CA (1) CA2566675A1 (en)
WO (1) WO2005112864A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US20050222687A1 (en) * 2004-04-02 2005-10-06 Gordana Vunjak-Novakovic Cartilage implant assembly and method for implantation
US20090291112A1 (en) * 2003-05-16 2009-11-26 Truncale Katherine G Allograft osteochondral plug combined with cartilage particle mixture
US7901457B2 (en) * 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20080220044A1 (en) * 2007-03-06 2008-09-11 Semler Eric J Cancellous construct with support ring for repair of osteochondral defects
US20090149893A1 (en) * 2007-12-05 2009-06-11 Semler Eric J Cancellous Bone Implant for Cartilage Repair
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US20060089723A1 (en) * 2004-10-25 2006-04-27 Murphy Kieran P Method for bone augmentation
US8852240B2 (en) * 2004-10-25 2014-10-07 Kieran Murphy, Llc Methods and compositions for fostering and preserving bone growth
CA2608016A1 (en) * 2005-05-11 2006-11-23 Unigene Laboratories, Inc. Improving bone formation and preservation by surgically inducing an increase in osteoblast activity coupled with the effect of administering pthrp or cgrp
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US8178099B2 (en) * 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
US20080200425A1 (en) * 2007-02-16 2008-08-21 Kurtz Seymour J Methods and compositions for regulating bone mineral density
US8435551B2 (en) * 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
JP2010526064A (en) * 2007-04-27 2010-07-29 ユニジーン・ラボラトリーズ・インコーポレーテッド Methods and compositions for nurturing and preserving bone tissue growth
JP5081598B2 (en) * 2007-12-06 2012-11-28 理想科学工業株式会社 Printing device
CA2717725A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
EP3453711B1 (en) 2011-09-02 2021-08-18 The Regents of the University of California Llp2a- bisphosphonate conjugates for osteoporosis treatment
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN108315446B (en) * 2018-05-12 2021-07-20 华中农业大学 SNP molecular marker related to sow limb hoof bone density

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3228393A (en) * 1962-08-28 1966-01-11 Arthur A Michele Hip replacement prosthesis
US3605123A (en) * 1969-04-29 1971-09-20 Melpar Inc Bone implant
US5192324A (en) * 1982-02-18 1993-03-09 Howmedica Inc. Bone prosthesis with porous coating
US4608052A (en) * 1984-04-25 1986-08-26 Minnesota Mining And Manufacturing Company Implant with attachment surface
US6319685B1 (en) * 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US5789234A (en) * 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
DE9011363U1 (en) * 1989-09-28 1990-11-15 Pfizer Hospital Products Group, Inc., New York, N.Y., Us
US5358533A (en) * 1992-02-19 1994-10-25 Joint Medical Products Corporation Sintered coatings for implantable prostheses
TW303299B (en) * 1993-07-22 1997-04-21 Lilly Co Eli
US5489306A (en) * 1995-01-03 1996-02-06 Gorski; Jerrold M. Graduated porosity implant for fibro-osseous integration
US6758849B1 (en) * 1995-02-17 2004-07-06 Sdgi Holdings, Inc. Interbody spinal fusion implants
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
AU734710B2 (en) * 1996-07-08 2001-06-21 Kyowa Hakko Kirin Co., Ltd. Calcium receptor active compounds
TW483881B (en) * 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
ATE484572T1 (en) * 1997-04-16 2010-10-15 Unigene Lab Inc DIRECT EXPRESSION OF PEPTIDES INTO CULTURE MEDIA
PE20000415A1 (en) * 1998-04-08 2000-05-21 Smithkline Beecham Corp CALCILITIC COMPOUNDS
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6620332B2 (en) * 2001-01-25 2003-09-16 Tecomet, Inc. Method for making a mesh-and-plate surgical implant
US6682567B1 (en) * 2001-09-19 2004-01-27 Biomet, Inc. Method and apparatus for providing a shell component incorporating a porous ingrowth material and liner
US20040242489A1 (en) * 2001-11-05 2004-12-02 Mitlak Bruce Howard Method for improving stability of a bone-connecting implant
WO2004028379A1 (en) * 2002-09-25 2004-04-08 Flock, Stephen, T. Microsurgical tissue treatment system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
REGINSTER J-Y. ET AL.: "Strontium ranelate: a new paradigm in the treatment of osteoporosis", EXPERT OPIN. INVESTIG. DRUGS, vol. 13, no. 7, 2004, pages 857 - 864, XP008116295 *
See also references of EP1748787A4 *
SKRIPITZ R. ET AL.: "Strong Effect of PTH (1-34) on regenerating bone. A time sequence study in rats", ACTA ORTHOP. SCAND., vol. 71, no. 6, 2000, pages 619 - 624, XP002319215 *
WHITFIELD ET AL: "Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis", TREATMENT IN ENDOCRINOLOGY, vol. 3, 2002, pages 175 - 190, XP008073017 *

Also Published As

Publication number Publication date
EP1748787A4 (en) 2009-09-23
CA2566675A1 (en) 2005-12-01
AU2005244829B2 (en) 2009-05-28
JP2007537281A (en) 2007-12-20
AU2005244829A1 (en) 2005-12-01
US20080051343A1 (en) 2008-02-28
US20080057051A1 (en) 2008-03-06
EP1748787A2 (en) 2007-02-07
US7648700B2 (en) 2010-01-19
WO2005112864A2 (en) 2005-12-01
US7531518B2 (en) 2009-05-12
US20050256047A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2005112864A3 (en) Method for fostering bone formation and preservation
WO2007014106A3 (en) System and method of delivering radiation therapy to a moving region of interest
WO2006083328A3 (en) Biologically active surfaces and methods of their use
TW200730211A (en) System and method of delivering radiation therapy to a moving region of interest
AR051446A1 (en) C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
WO2005123094A3 (en) Treatment or prevention of skin conditions or tissue conditions in animals using boryloxypyridylmethanones
WO2005042700A3 (en) Use of hedgehog pathway inhibitors in small-cell lung cancer
NO346765B1 (en) Lottery system and method with real-time growing jackpot
ATE399507T1 (en) METHOD AND SYSTEM FOR CRYOABLATION OF FIBROADENOMAS
WO2008039930A3 (en) Method and apparatus for promoting restorative sleep
WO2005123116A3 (en) Compositions and methods for treating or preventing oxalate-related disease
WO2005027993A3 (en) Vascular access preservation in hemodialysis patients
WO2004010937A3 (en) Method of treating cancer
WO2006025028A3 (en) Novel classification method of blood cells and tailor-made therapy and prevention based thereupon
DE602005015841D1 (en) AROYL-O-PIPERIDINE DERIVATIVES FOR TREATING PROBLEMS ASSOCIATED WITH DIABETES
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
ATE513577T1 (en) METHOD AND DEVICE FOR PREDICTING ARRHYTHMIA USING DIURNAL HEART RATE
WO2002092013A3 (en) Methods for treating liver disease and liver damage with growth hormone and foxm1b
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
EA201101300A1 (en) METHOD OR SYSTEM BASED ON BIOMARKERS INTENDED FOR MONITORING TREATMENT
EP2633856A3 (en) ATP citrate lyase inhibitors for treating cancer
WO2006031607A3 (en) A method of treating cancer
WO2006023910A3 (en) Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
EP1977788A3 (en) System and method of delivering radiation therapy to a moving region of interest
PL2497486T3 (en) Method for treating diseases caused by fungi associated with changes of qualitative and/quantitative composition of blood extracellular DNA

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005244829

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005760624

Country of ref document: EP

Ref document number: 2007513355

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2566675

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005244829

Country of ref document: AU

Date of ref document: 20050512

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005244829

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580023744.4

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005760624

Country of ref document: EP